NRIXNurix Therapeutics, Inc.Signing up patients
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL)
9Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +9.2
3 insiders sold shares within a month
Since Oct 30, 2026 · was worth 10, fading over time
Worry score9
Score over time
- Stage
- Phase 2
- Patients
- 100 (planned)
- Started
- Oct 15, 2025
- Main results expected
- Jan 2028
- Fully finished
- Oct 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective response rate without partial response with lymphocytosis (PR-L) as determined by an Independent Review Committee (IRC)
Measured over: Up to approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 9.2, since 2026-10-30, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07221500 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC